GLPwatch
[An orally administered glucagon-like peptide 1 (GLP1) analogue: A landmark in the treatment of type 2 diabetes].
Med Sci (Paris) · 2021
Last updated 2026-09-22Semaglutide is the first GLP-1 drug available in an oral form for treating type 2 diabetes, previously only offered as a weekly injection. In clinical trials, it improved blood sugar control, with participants taking 14 mg daily seeing a 1.2% reduction in blood sugar levels after 26 weeks. The drug uses a special coating to protect it from stomach acid and allow absorption.
AI summary of the abstract below.
| Journal | Med Sci (Paris), 2021 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.06 |
| NIH percentile | 5 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Semaglutide is the first peptide to receive European marketing authorization for oral administration in the treatment of type 2 diabetes. The active molecule is the same as the one marketed for weekly subcutaneous administration. It is associated with a new excipient, which protects it from degradation by gastric pepsin and allows its absorption in the stomach. This article presents the pharmacological characteristics of this drug, as well as a critical analysis of the results of the main phase III clinical trials.
Verbatim abstract via PubMed 33492219 ↗